CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Kringle Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Kringle Pharma Inc
207
Saito Bio Incubator, 7-7-15, Saitoasagi
Phone: +81 726418739p:+81 726418739 IBARAKI-SHI, OSK  567-0085  Japan Ticker: 48844884
Business Summary
Kringle Pharma Inc is a Japan-based company mainly engaged in the development of pharmaceuticals. The Company is involved in the research and development of therapeutic agents for intractable diseases using hepatocyte growth factor (HGF) protein. HGF has versatile bioactivity that is responsible for tissue or organ regeneration and protection such as cell proliferation promotion, cell motility promotion, anti-apoptosis, morphogenesis induction, and angiogenesis. HGF has a therapeutic effect on chronic fibrotic diseases such as liver cirrhosis, chronic renal failure, pulmonary fibrosis and cardiomyopathy. HGFs target diseases are Atrophic lateral sclerosis (ALS), Acute renal impairment, Vocal scar and others. The Company is involved in the general new drug development processes such as basic research, non-clinical trials and manufacturing, clinical trials, approval application and authorization, marketing and expansion of indications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20239/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Representative Director KiichiAdachi 54 12/1/2016 12/1/2004
Director of Business Administration, Director KoichiMurakami 62 12/24/2021 12/24/2021
Director of Pharmaceutical Development, Director DaishinHayata 47 12/1/2022 12/1/2022
4 additional Officers and Directors records available in full report.

General Information
Number of Employees: 13 (As of 9/30/2023)
Outstanding Shares: 6,511,513 (As of 2/9/2024)
Shareholders: 2,854
Stock Exchange: TYO
Fax Number: +81 726418730


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024